Shanghai Jindi Kyushu Pharmaceutical (Anyang) Co., Ltd.
Switchboard: 0372--6250880 Fax: 0372--6250890
Marketing Center: 0372--6250892
Sales of APIs:
Mr. Fu: 135-6903-7762 (Foreign Ministry)
Mr. Chen: 134-0372-0000
Mr. Ye: 139-4953-3698
Mr. An: 151-3101-5755
Mr. Wang: 138-3721-3711
Mr. Zhao: 136-6372-8999
Mr. Niu: 139-4952-8999
Human Resources Recruitment: Ms. Song: 155-1878-5470
Company Address: Tangyin Road, Tangyin Industrial Cluster, Anyang City, Henan Province
Company zip code: 456150
The company's three series of drugs: bio-fermentation raw materials, synthetic raw materials, small-volume injections have passed the 2010, 2015 version of the drug quality GMP certification; environmental protection system has passed the Henan Province environmental protection acceptance and received the sewage permit issued by Anyang City 2017; the company now has Complete water, electricity, steam, wind, cold power system and environmental protection, quality inspection, biological laboratory and other ancillary equipment and facilities; the company has convenient transportation, the industrial park where the factory is located is close to Beijing-Guangzhou Railway, Beijing-Zhuhai Expressway, and high-speed rail; Enterprises have long enjoyed the preferential investment policies for government service packages.
(1) Small-volume injection: At present, there are three production lines in the small-volume injection injection workshop, and 75 approval documents have been obtained. The production capacity of single shift is 50 million pieces/month, the output value is 800-10 million yuan/month, and the annual output value is 100 million yuan. In order to give full play to the advantages of complete and multi-applications of products, timely adjust marketing strategies and increase market share, according to the changes in the company's best-selling market, the goal of aiming at an annual output value of 200 million yuan will continue to grow stronger and bigger. The first step is to expand production, and the single-shift production will become double-shift production. The monthly output will reach 90 million, the output value will reach 15-16 million yuan/month, the annual output will be 1 billion, and the output value will be 1.5-160 million yuan. The profit is 16 million yuan. The second step is to optimize the products and make the unique varieties better and increase the high profits. Such as: fluorouracil, sodium diclofenac, etc.; especially hydroxycobalamin hydrochloride, the domestic one of my family has an injection approval, and now we are developing a drug substance approval. The company will continue to play the role of raw materials, injections have the unique advantages of approval, further optimize the process, and make the unique products better and stronger.
(2) Biological fermentation raw materials: Our company has a biological fermentation workshop with a total volume of 856 cubic meters, and the extraction process is advanced. It can produce a variety of bio-fermentation products, and has already possessed “multi-tailed” production capacity; it is currently cooperating with high-tech bio-tech companies such as Beijing, Shanghai and Hebei to produce multi-species bio-fermentation products using the company's advanced production platform. The company has successfully developed and researched the biological fermentation varieties: sodium hyaluronate, cyclic adenosine monophosphate, adenosine monophosphate, and adenosine monophosphate, which are the new economic growth points of the company.
(3) Chemical synthesis drugs: The company has three workshops for chemical synthesis drugs. Existing varieties: diclofenac sodium, diclofenac potassium, hydrochlorothiazide, cinnarizine, nitrendipine, propafenone hydrochloride.
Varieties are being developed: adenosine monophosphate, cyclic adenosine monophosphate, and hydroxycobalamin hydrochloride.